Pirtobrutinib monotherapy (continuous, BRUIN schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-PIRTOBRUTINIB |
|---|
| ID | REG-PIRTOBRUTINIB |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
BRUIN trial (Mato 2023): r/r CLL/SLL after prior cBTKi (median 3 prior lines, ~80% with prior cBTKi, ~50% with prior BCL2i) — ORR 73%; in BTK-C481-mutated subset ORR ~71%; mPFS ~19.6 mo. Approved 3L+ post-cBTKi + post-BCL2i in CLL/SLL. Distinct binding mechanism (non-covalent, C481-independent) overcomes resistance to ibrutinib / acalabrutinib / zanubrutinib. Particularly active in TP53-mutated CLL where conventional chemoimmuno + chemoSCT fail.
Used By
Indication
IND-CLL-3L-PIRTOBRUTINIB- IND-CLL-3L-PIRTOBRUTINIB